Searching for FUE hair transplant side effects can make the process feel full of complications, dangerous outcomes, and scary risks. In reality, most FUE patients experience short-term, manageable side effects, while serious problems are rare. This guide walks through what is truly normal, what is uncommon, and when to seek help.
What are the side effects of hair transplant surgery?
The side effects of hair transplant surgery are mostly mundane: short-term redness, swelling, scabbing, mild discomfort and temporary shedding of hairs as the scalp recovers. There are too many to explain in a single short section, so we will walk through every important category in more detail below.
FUE hair transplant side effects
FUE side effects range from familiar short-term healing changes to less common cosmetic, nerve-related and wound problems, plus rare systemic or anaesthesia-related complications. We have been asked about almost all of these at our Chicago hair transplant clinic. The sections below separate expected recovery effects from problems that deserve closer assessment.
Common & expected FUE hair transplant side effects
These are the more familiar short-term effects seen during FUE recovery. They do not affect every patient, and their frequency varies: swelling can be common, while temporary numbness and shock loss are much less universal. The important pattern is that expected recovery effects should improve rather than persist or progressively worsen.
Redness, swelling & bruising
Redness, swelling and mild bruising can occur after FUE. In a 152-patient FUE study, forehead swelling affected 69.74% within two days and redness 3.95% at seven days. Swelling is a common hair transplant side effect and can extend toward the eyelids, causing facial swelling after hair transplant surgery.
Mild pain, tenderness & tightness
Mild pain, tenderness and tightness usually settle quickly after FUE. In a 241-patient study comparing harvesting methods, the 39 FUE patients reported significantly less postoperative pain than FUT patients, with only minimal pain even on day one. Tenderness or tightness should gradually ease as swelling and the small wounds heal.
Itching, dryness & flakiness
Itching, dryness and flaking can develop as the scalp heals. In a 152-patient FUE study, donor-site itching affected 4.61% at seven days and again at two months, while dryness affected 5.26% at two months. An itchy scalp after hair transplant surgery should improve rather than progressively worsen.
Scabbing, crusting, oozing & pinpoint bleeding
Scabs, crusting, oozing and pinpoint bleeding can occur while sites heal. In a 152-patient FUE study, pain during crust removal affected 1.97% at seven days; hair transplant scabs should soften with washing rather than picking. After a no shave FUE hair transplant, crusts can catch in existing hair.
Temporary numbness & tingling
Temporary numbness, tingling and altered sensation can affect the donor or recipient scalp after hair transplantation, but these symptoms usually improve during recovery. In a 152-patient FUE study, recipient-site numbness affected 9.87% at 7 days and only 1.32% at 2 months during follow-up after surgery.
Sensory changes are not limited to reduced feeling. Hyperesthesia means unusually heightened sensitivity, while dysesthesia can feel unpleasant, burning or prickling. In a multicenter retrospective review of 552 hair-restoration patients, 19 (3.4%) reported postoperative hyperesthesia in the donor or recipient scalp.
Because that study covered hair-restoration surgery more broadly and included patients with previous procedures, it does not give an FUE-specific rate. FUE-specific evidence is smaller: in a two-center FUE series of 52 men, one patient developed donor-area paresthesia, which resolved after 21 days.
Temporary sensory change is therefore different from the chronic numbness, chronic pain and neuroma complications covered below. Numbness that worsens rather than improves, persists for months, or is accompanied by severe burning, shooting pain or marked tenderness should be assessed by the treating surgeon.
Temporary shedding & shock loss
Temporary shedding, or shock loss, is a recognized post-transplant effect that can involve transplanted hairs, nearby native hairs, or even the donor area. In a 621-patient FUE study, recipient-site shock loss affected 14 of 67 women (20.9%) and 9 of 554 men (1.6%) in that cohort.
That temporary loss does not necessarily mean the grafts have failed. Transplanted shafts commonly shed during early recovery, while recipient-site shock loss refers to temporary loss of existing native hairs around the transplanted area. Patients sometimes describe this temporary dip in density as the “ugly duckling phase hair transplant” period, when the scalp can look worse before visible regrowth begins.
Women should be particularly aware of temporary shedding. In the 621-patient study, female sex was the only risk factor identified for recipient-site shock loss, with an odds ratio of 30.18. A separate retrospective study of 195 women found telogen effluvium in 45.1% at the recipient site and 6.7% at the donor site. That makes temporary shedding one of the more relevant female hair transplant side effects to discuss before surgery.
Donor-area shock loss, or donor effluvium, is less discussed but can happen after FUE as well. A four-patient case series described patchy donor-area shedding appearing 2–3 weeks after surgery. The authors found features consistent with a healing response and proposed trauma and compromised blood supply to existing hairs as likely contributors.
Shock loss can sometimes appear patchy enough to create temporary bald-looking areas, but published evidence does not show that obvious bald patches are common after FUE. Patchy shedding has been documented in both recipient and donor areas, including the donor-area cases above, but the available studies do not provide a dependable incidence rate specifically for visible bald patches.
A common concern is this: does everyone get shock loss after hair transplant surgery? No. In the 621-patient study, 23 of 621 patients (3.7%) developed recipient-site shock loss overall. The large difference between men and women also shows why individual risk varies, and most temporary shedding is expected to recover as the hair cycle normalizes.
Less common hair transplant effects
The effects below are less common and can involve healing, graft survival, donor appearance, pigmentation, scarring or inflammatory disease after hair restoration procedures. Some are temporary and treatable, while others can leave lasting cosmetic changes. Follow-up matters because the right response depends on what is actually causing the problem.
Folliculitis, pimples, ingrown hairs & cysts
Folliculitis after hair transplantation is relatively common and usually treatable, although rates vary widely by study and technique. A 2024 multicenter retrospective study of 1,317 patients found postoperative folliculitis in 12.11%, while an older 533-procedure series reported folliculitis in 1.0%, showing how incidence depends on definitions and practice.
The 1,317-patient study also identified several factors associated with higher odds of postoperative folliculitis. These included receiving 4,000 or more grafts (OR 4.818), transplant density above 45 grafts/cm² (OR 2.152), and waiting more than three days for the first postoperative nursing session (OR 1.555). These are associations rather than guarantees that folliculitis will occur.
Not every post-transplant pimple or pustule is the same. A 73-patient retrospective series, which was predominantly FUT rather than FUE, recorded sterile folliculitis in 23.29% and bacterial folliculitis in 10.96%. The authors discussed ingrown hairs among the possible explanations for sterile folliculitis, but did not establish one single cause. This distinction matters because a sterile inflammatory bump is different from a true bacterial infection.
Cysts and buried grafts are rarer technical complications. In a 158-patient FUE study, two patients (1.3%) developed mild folliculitis and one (0.6%) had a graft inadvertently buried in the dermis; the buried graft was removed with a needle. An earlier FUE case report documented subdermal cystic swellings containing full-thickness follicular-unit grafts after grafts had been pushed beneath the skin and left there.
Small, short-lived bumps are therefore not automatically a sign that something has gone badly wrong, but persistent, increasingly painful, hot, spreading, draining or recurrent lesions should be assessed by the transplant team. Buried grafts or deeper cystic nodules may need direct treatment rather than simply waiting for them to settle.
Graft dislodgement, graft loss & poor growth
Graft dislodgement and partial graft loss are uncommon but documented after hair transplantation. In a 10-year series of 2,896 patients, 8 patients (0.28%) experienced graft dislodgement within the first 24 hours, while 5 patients (0.17%) had partial loss of implanted hair. Poor growth can also occur without visible graft loss.
Dislodgement means a newly implanted follicular unit has physically left its recipient site; it is not the same as the normal shedding of the visible hair shaft. In the series above, all eight dislodgements occurred during the first 24 hours. A bumped or rubbed recipient area that develops fresh bleeding should be reported to the transplant team rather than manipulated or reinserted at home.
Poor growth is different: the graft can remain in place but fail to produce the expected hair. Direct experimental work shows why graft handling matters. A controlled microscopy study of follicular unit grafts subjected them to crushing, bending, stretching or three minutes of drying; major structural damage was seen in the dried grafts, while the other groups showed no detectable changes. An earlier human micrograft “crush study” also reported reduced yields with less skilled handling and concluded that iatrogenic trauma can contribute to poor growth. These studies are older and do not provide a modern FUE failure rate, but they support careful graft handling and hydration as biologically important.
Timing matters when judging the result. Early shedding is expected and is covered above; it should not be counted as graft loss. If an area remains noticeably sparse after the expected regrowth period, the clinic can assess whether the issue is delayed growth, poor graft survival, progression of surrounding native hair loss, or a design or density problem. Depending on the cause and available donor supply, management may range from observation or medical treatment to a later corrective transplant.
Inflammatory/scarring scalp conditions after transplantation
Inflammatory or scarring scalp disease after hair transplantation appears rare, but it can cause permanent follicle loss if missed. In a 17-patient retrospective series of post-transplant lichen planopilaris, onset occurred 4–36 months after surgery, and 12 patients (70%) showed perifollicular redness or scale on examination.
Lichen planopilaris (LPP) is a primary scarring alopecia. In that series, all 17 diagnoses were confirmed with scalp biopsy, itching was the most common symptom, and the patients had been referred for assessment of suboptimal growth after transplantation. The study supports an association with transplantation, but it does not establish how often LPP occurs or prove that surgery caused it.
A separate 10-patient case series of post-transplant inflammatory complications included seven patients who had undergone FUE and three who had undergone FUT. Seven were diagnosed with LPP, two with erosive pustulosis of the scalp and one with superficial folliculitis. None had documented inflammatory scalp disease before surgery. Because the study looked only at patients referred with inflammatory complications, it cannot tell us how common these conditions are across all hair-transplant patients.
Persistent itching, perifollicular redness or scaling, pustules, crusting, unexpected continuing hair loss or poor graft growth months after transplantation deserve clinical assessment rather than being assumed to be routine healing. Dermoscopy and, where indicated, scalp biopsy can help identify inflammatory scarring disease. Careful preoperative scalp examination is also important because subtle inflammatory disease may otherwise be missed.
Donor texturing, pitting & cobblestoning
FUE does not leave a linear donor scar, but each extraction creates a small circular wound that can heal with visible texture change or pitting. In a five-patient study using 0.8-mm punches, mean scar diameters measured 0.598–0.668 mm after one month, depending on punch design.
That study was too small to establish how often visible texturing occurs. A separate 35-patient original FUE study found that extraction technique significantly changed wound surface area and the mass of skin removed, supporting the practical point that punch alignment and tissue injury influence donor-site scarring rather than all FUE wounds healing identically.
Classic hair transplant cobblestoning is different: it refers to raised, palpable graft borders in the recipient area rather than donor extraction pits. A 1991 primary report described visible borders around transplanted plugs and evaluated a suturing method intended to reduce them. Because the report involved older plug-era transplantation, it does not tell us how often cobblestoning occurs after modern FUE.
Pitting describes a depressed contour rather than a raised one. Modern primary studies do not give a dependable rate for either pitting or cobblestoning after contemporary FUE, so a precise percentage would be misleading. Persistent bumps, depressions, or obvious donor texture after healing warrant clinical review, particularly when they remain cosmetically noticeable.
Uneven density & asymmetry
Uneven density, asymmetry and unnatural hair direction are cosmetic complications rather than medical emergencies, but they can be difficult to correct. A 2026 multicenter study followed 20 men undergoing FUE repair of poorly designed or excessively low hairlines; 28% required a second corrective procedure, although 95% were ultimately satisfied.
Importantly, some asymmetry is normal. A 2025 study of 125 East Asian men with minimal hair loss found an average 22.2-degree difference between right- and left-side hair growth angles, with only 8.8% showing greater leftward angulation. That means a perfectly mirrored hairline is not necessarily the most natural-looking goal.
The 2026 repair series specifically describes problem hairlines as excessively low, rounded or lacking a natural transition zone. Hair caliber matters too: a 24-woman revision study treated thick donor hairs creating an unnatural frontal edge after previous transplantation, showing that surviving grafts can still look wrong when their size or placement does not blend naturally.
Correction depends on the problem. Low-density areas may be blended with additional grafts, while misplaced or badly angled follicular units may need extraction or repositioning. In the 2026 repair series, 60% of extracted units were reimplanted nearby, 20% elsewhere and 20% discarded, showing why revision surgery often requires individualized planning.
Overharvesting & donor depletion
Overharvesting removes too many follicles from the donor area and can leave permanent, visible thinning. In a study of 103 men after FUE, donor sites judged “poor” averaged 94.9 hairs/cm² versus 127.8 hairs/cm² in the “good” group; 7 of 10 men below 105 hairs/cm² had poor appearance.
Donor depletion may look diffusely see-through or patchy and “moth-eaten,” especially when extractions are concentrated rather than spread evenly. Conventional FUE removes whole follicular units from the donor scalp, so those extracted follicles are no longer available there. A 10-patient donor-density study found that an average 35.44% of donor hairs were extracted from the sampled areas, with substantial variation between patients. The study was not designed to define an overharvesting threshold, but it illustrates how substantially baseline density and extraction density can vary.
There is no single graft number or percentage that is safe for every donor area. In a multicenter study of 119 men with androgenetic alopecia, mean safe-donor hair density was 137.45 ± 30.11 hairs/cm², and the investigators proposed retaining at least 106.88 hairs/cm² (60 follicular units/cm²). Those figures came from Chinese male patients, so the safe density for an individual patient may differ with ethnicity, hair type, scalp characteristics and other factors.
Good donor planning therefore considers more than the number of grafts requested. Baseline density, hair caliber, contrast between hair and scalp, the size of the safe donor zone, previous procedures, likely future hair loss and the patient’s preferred hair length all affect how much extraction can be hidden. If significant depletion has already occurred, options may include wearing the hair longer, scalp micropigmentation or carefully planned use of remaining scalp or non-scalp donor hair, but prevention preserves the widest range of future choices.
Hypopigmentation & hyperpigmentation
Hypopigmentation can leave small pale dots at FUE extraction sites, while hyperpigmentation is reported less often; reliable modern incidence rates are not available. In one published FUE case, permanent recipient-site leucoderma developed after a 2,500-hair transplant, appearing within one month and persisting three years later.
At the donor site, each FUE punch creates a small wound that can heal with fibrosis and reduced pigmentation. A 35-patient FUE study directly measured donor-site injury and found that harvesting technique significantly affected both wound surface area and the amount of skin removed. The study supports tissue injury as a mechanism for visible pale extraction marks, but it did not establish how often clinically noticeable hypopigmentation occurs.
Persistent pigment loss has also been documented at the recipient site. In the published case of permanent leucoderma after hair transplantation, a 25-year-old woman developed variegated hypopigmentation about one month after a 2,500-hair FUE procedure, and it remained present three years later. That case confirms that persistent depigmentation can occur, but a single report cannot tell us how likely it is.
Hair-transplant-specific primary evidence for postoperative hyperpigmentation is much more limited, so a reliable modern incidence rate is not available. Temporary darkening can occur during wound healing, while persistent, expanding or sharply demarcated pigment change warrants assessment rather than being assumed to be a routine part of recovery.
Hypertrophic & keloid scarring
Hypertrophic or keloid scars are uncommon after hair transplantation, especially after FUE, but they can occur. In a 533-procedure retrospective series, keloids were reported in 0.4% and enlarged scars in 1.2%; modern FUE-specific incidence is not established, and published FUE evidence is mainly individual case reports.
These two scar types are not identical. Hypertrophic scars remain within the boundaries of the original wound, whereas keloids extend beyond them and can continue growing. The 533-procedure study covered surgeries performed between 1995 and 2006, so those figures do not represent the risk specifically for contemporary FUE.
Modern FUE case reports confirm that significant donor-site keloids can still occur. A 2017 case report described a 30-year-old man who developed itching about six weeks after FUE, followed by progressively enlarging raised donor-site plaques; examination also found a separate chest keloid. A later 2020 FUE case involved a 35-year-old man with no previous similar scars, showing that a negative history cannot completely rule the complication out.
Previous keloids or a strong tendency toward raised scarring are therefore important to disclose before surgery, but they do not perfectly predict what will happen. A scar that becomes increasingly raised, extends beyond the extraction wound, or remains itchy, painful or tender deserves assessment. In the 2020 report, silicone gel sheeting plus intralesional triamcinolone produced acceptable regression after four treatment sessions, while the 2017 case responded poorly to two triamcinolone sessions before follow-up was lost.
Nerve-related hair transplant complications
Temporary numbness is common and usually short-lived, but a small number of patients can experience more persistent nerve-related problems. Among the risks of hair transplant surgery, lasting numbness, neuropathic pain and neuroma are uncommon, and the available evidence suggests they relate to nerve irritation or injury rather than routine healing.
Chronic numbness
Chronic numbness after FUE appears uncommon, although persistent sensory changes are documented. In a retrospective series of 1,030 primary hair transplants, long-term numbness or paresthesia was reported in about 2% of patients, mainly in temporal or occipital areas. A separate 152-patient FUE study found numbness in 1.32% at two months.
The 152-patient study shows how sharply sensory symptoms can fall during recovery: recipient-site numbness was reported in 9.87% at seven days but only 1.32% at two months. Numbness was not among the complications listed at the six-month follow-up, although the study does not give the exact recovery date for the two patients who still reported it at two months.
A 10-year series of 2,896 hair-transplant patients recorded numbness in 18 cases. Most sensory complaints settled within weeks, while one patient had donor-area numbness for almost four months before it resolved spontaneously. Importantly, that prolonged case followed FUT strip harvesting rather than FUE, so it does not tell us the rate of prolonged numbness after FUE.
The same authors note that deeper FUE punch penetration can potentially traumatize underlying nerves, while strip harvesting can affect larger sensory nerves in the donor scalp. Persistent numbness that is not steadily improving, or numbness accompanied by burning, shooting pain or a tender focal spot, deserves review because those symptoms may point to a more significant nerve injury or neuroma. Good primary data on truly permanent numbness after contemporary FUE remain limited.
Chronic pain
Chronic neuropathic pain after hair transplantation appears rare, and dependable modern incidence data are lacking. In one published case, a 72-year-old man developed immediate sharp, shocking occipital pain during posterior scalp harvest that persisted for years; pulsed radiofrequency treatment later produced more than 80% relief for five months.
Chronic pain is different from the normal tenderness expected during early healing. Neuropathic symptoms may feel burning, shooting, electric, prickling or unusually sensitive rather than simply sore. In a 104-patient FUE series, four patients developed a burning sensation in the donor area. The authors did not report how long that symptom lasted, so the study cannot tell us how often truly chronic pain occurs after FUE.
The better-documented chronic case involved full-thickness posterior scalp harvesting rather than contemporary FUE. The patient developed pain and sensory loss in the distribution of the lesser occipital nerve; local anaesthetic nerve blocks temporarily abolished the pain, while oral analgesics, neuropathic medicines, acupuncture and later botulinum toxin provided limited or temporary benefit. Pulsed radiofrequency neuromodulation subsequently produced complete relief initially and more than 80% relief for five months, with similar benefit after repeat treatment.
Persistent burning, shooting or electric pain, marked hypersensitivity, pain from light touch, a focal tender point, or pain accompanied by continuing numbness deserves assessment rather than being treated as routine postoperative soreness. The evidence confirms that chronic neuropathic pain can occur after hair transplantation, but it remains too sparse to provide a dependable incidence figure for modern FUE.
Neuroma
Neuroma after hair transplantation is documented but appears exceptionally rare, with no reliable incidence rate for modern FUE. A 2015 case report described a 37-year-old woman who developed chronic occipital pain seven years after strip surgery; a 5 × 7 mm neuroma was excised and pain resolved within one month.
A post-traumatic neuroma is not a cancerous tumor. It is a reactive proliferation of nerve tissue that can develop after a nerve is injured. In the reported patient, a small hairless lesion in the left occipital donor area became slightly raised when pressed, and compression produced tingling that radiated toward the top of the head. Histopathology after excision confirmed the diagnosis.
The published hair-transplant case involved follicular-unit strip surgery rather than FUE, so it does not tell us how often neuroma occurs after contemporary FUE. The authors proposed injury to nerves beneath the subdermal donor layer as the likely mechanism. Persistent focal pain, a tender or palpable nodule, or reproducible tingling when a specific donor-site spot is pressed deserves assessment rather than being assumed to be routine postoperative sensitivity.
Wound & local tissue hair transplant risks
Like any surgery, FUE can cause local wound and tissue complications, although published series suggest serious problems are uncommon. Early assessment can limit damage, but some complications, particularly necrosis, deeper infection or significant bleeding, can still threaten grafts or leave scarring. Increasing pain, spreading redness, drainage or tissue discoloration should not be ignored.
Infection
Post-transplant infection appears uncommon in published series, but it can affect donor or recipient wounds and occasionally threaten grafts or scalp tissue. In a 533-procedure retrospective series, infection occurred once (0.2%); a separate 2,896-patient series recorded two infections (0.07%), both in patients with diabetes.
The larger 10-year series of 2,896 patients does not establish that diabetes caused those infections or quantify a diabetes-specific risk; it simply records that both affected patients had diabetes. The finding still supports careful medical screening and good control of relevant health conditions before surgery, but it does not establish a diabetes-specific risk level.
Modern FUE infections can also complicate other local tissue problems rather than occurring in isolation. A 2026 FUE case report described a 46-year-old man who developed recipient-site necrosis followed by secondary Pseudomonas aeruginosa infection. Dusky discoloration appeared on postoperative day two, extensive necrosis with yellow crusting was present by day ten, and culture-guided systemic antibiotics plus wound care controlled the infection. The area healed with residual atrophic scarring and permanent alopecia at 12 weeks.
Systemic infection is much rarer but deserves urgent attention. In a published MRSA case, a 53-year-old man developed a febrile illness and blurred vision one week after transplantation, with blood cultures positive for methicillin-resistant Staphylococcus aureus and treatment requiring intravenous antibiotics. That is an extreme case rather than a typical postoperative infection, but it shows why fever or rapidly worsening local changes should not be dismissed as routine healing.
Abscess
Scalp abscess after hair transplantation is rare, and modern incidence is not well established. In a 2023 case report, a previously healthy 53-year-old man developed painful, draining scalp nodules 19 days after transplantation; about two months after surgery, surgeons incised and drained five abscesses caused by Mycobacterium abscessus.
An abscess is a localized collection of infected material rather than the small pimple-like bumps that can accompany folliculitis. In that case, the patient had redness, tenderness, fluctuance and spontaneous purulent drainage but remained afebrile with normal blood tests. Several conventional antibiotic regimens failed, and the organism was identified only after prolonged culture, illustrating why persistent or recurrent abscesses may need drainage, deep-tissue sampling and targeted antimicrobial treatment rather than repeated empirical antibiotics.
A separate 2016 hair-transplant case described a 28-year-old man who developed scalp nodules two months after surgery; incision and drainage produced material that cultured M. abscessus after two weeks. More recently, a 2026 cluster report used genomic testing to link two M. abscessus surgical-site infections occurring after hair transplantation in Turkey. These reports establish that abscesses can occur after transplantation, including from unusual organisms, but they do not provide a dependable incidence rate.
A rapidly enlarging, fluctuant or increasingly painful lump, especially one producing pus or recurring after antibiotics, should be assessed rather than squeezed or drained at home. Treatment depends on the cause and may include incision and drainage, culture and organism-specific medication; delayed diagnosis can prolong infection and increase the risk of scarring or graft loss.
Pyogenic granuloma
Pyogenic granuloma is a very rare growth that can develop at a healing transplant site and may bleed easily. In a 533-procedure hair-transplant series, it occurred once (0.2%). An earlier case report described multiple pyogenic granuloma-like lesions arising specifically at punch-graft recipient sites after transplantation.
The evidence base is extremely limited. The 1985 authors described the lesions as an unusual complication and said their cause and development remained unclear. Importantly, that report involved older punch-graft transplantation, so it does not tell us how often pyogenic granuloma occurs with modern FUE.
A new red growth that enlarges quickly or repeatedly bleeds after a transplant deserves clinical review rather than being assumed to be an ordinary pimple or crust. The available hair-transplant literature supports recognizing pyogenic granuloma as a possible complication, but it does not provide enough modern FUE data for a dependable incidence figure.
Haematoma
Haematoma is an uncommon complication of hair transplantation, while small amounts of pinpoint bleeding are expected after FUE. In a retrospective series of 533 hair-transplant procedures, significant bleeding was recorded in one procedure (0.2%). A haematoma forms when continued bleeding collects beneath the scalp rather than escaping from the wound.
A true haematoma is different from the light oozing or tiny spots of blood that can occur around fresh extraction and recipient sites. It is more likely to appear as a localized swelling that becomes firm, tender, increasingly bruised or larger over time. An expanding collection or bleeding that will not stop should be reported promptly because the surgical team may need to control the bleeding source or drain the collection.
Persistent bleeding deserves particular attention when blood clotting is altered. A published hair-transplant case report described excessive and persistent bleeding in a patient taking warfarin. That does not mean anticoagulant treatment automatically rules out transplantation, but it does show why the surgeon needs a complete medication and bleeding history. Patients should never stop prescribed anticoagulants or other medicines without guidance from the clinician who manages them.
Scalp necrosis
Scalp necrosis is a rare but serious complication in which part of the donor or recipient skin loses its blood supply and dies. In a 2012–2021 series of more than 10,000 hair-transplant patients, three developed recipient-site necrosis; three of four total treated cases healed within 2–3 weeks.
Most published reports concern the recipient area, but donor-site necrosis after FUE has also been documented. A published FUE donor-site case resulted in cicatricial alopecia of part of the occipital scalp and ultimately required reconstructive surgery with tissue expanders.
Smoking, hypertension and diabetes have all appeared in published cases of scalp necrosis, but the strength of each risk is uncertain because most evidence comes from patients who already developed the complication. In an 18-patient FUE necrosis series, smoking was the most frequently identified factor, with hypertension and diabetes also present. The patients had received an average of about 3,899 follicular units in a single session, and all experienced scarring and graft failure. These findings highlight factors seen among affected patients, but they do not show how much any one factor raises an individual patient’s risk.
Early changes can be more important than the final black eschar. A 2026 FUE case report described dusky discoloration by postoperative day 2, progressing to extensive necrosis and yellowish crusting by day 10; secondary Pseudomonas aeruginosa infection was cultured. At 12 weeks the area had healed, but with an atrophic scar and permanent hair loss in the affected region.
Prompt assessment matters because tissue and grafts may still be salvageable. In the four-patient series above, three patients treated promptly had necrosis confined and healed within 2–3 weeks with partial graft survival, whereas delayed or inappropriate early treatment in the fourth patient was followed by deeper, more extensive tissue loss and complete graft loss in the affected area. Management depends on severity and cause and can include wound care, treatment of secondary infection and, in more severe cases, surgical debridement.
Systemic & anaesthesia-related dangers of hair transplant
Systemic and anaesthesia-related events can sound frightening, especially when mixed with hair loss myths and online horror stories. Published series show that transient events such as vasovagal reactions or hiccups can occur, while severe allergy, anaesthetic toxicity, thrombosis, sepsis, cardiac arrest and death are documented far more sparsely.
These are not all the same type of risk, and several are not specific to FUE. Careful screening, an accurate medication history, appropriate dosing, monitoring and treatment in a properly equipped medical setting are important because rare serious events require rapid recognition and response.
Fainting, vasovagal reactions & blood pressure changes
Fainting and sudden blood-pressure changes can occur during hair transplantation, but they were uncommon in a large primary series. Among 2,896 patients, seven developed vasovagal reactions (0.24%) and one experienced a hypertensive crisis (0.03%). No major or life-threatening intraoperative complication was reported in that cohort.
A vasovagal reaction is a reflex response in which heart rate and blood pressure can fall, sometimes causing lightheadedness or fainting. The 2,896-patient study recorded seven such events and reported that they were managed, but it did not provide enough detail to identify specific triggers, duration or patient-level risk factors. The 0.24% figure therefore describes that surgeon’s series rather than a universal FUE rate.
The single hypertensive crisis in the same study is particularly useful because the circumstances were documented. The patient was taking propranolol for anxiety but had not disclosed it; after local anesthetic containing adrenaline was administered, a hypertensive crisis occurred. Surgery was stopped, the blood pressure was controlled and the remaining grafts were then implanted. One event cannot establish how often this interaction occurs, but it underlines why the transplant team needs a complete medication history before surgery.
Feeling faint during or immediately after a procedure should be reported to the clinical team rather than simply trying to stand up or walk it off. Likewise, markedly abnormal blood pressure during surgery requires medical assessment. Published hair-transplant data do not provide a dependable rate for every form of transient blood-pressure change.
Hiccups
Hiccups are an unusual but documented complication after hair transplantation and may begin during or soon after surgery. In a 2,896-patient series, 6 patients (0.21%) developed hiccups; a separate 533-procedure retrospective study reported the same complication in 0.2%, supporting that it is uncommon in published cohorts.
The larger series provides useful firsthand treatment information: all six patients with hiccups were given chlorpromazine 25 mg twice daily, and the authors reported relief within one to two days. That is an outcome from this particular cohort, not evidence that every post-transplant episode needs medication or that patients should self-treat.
The exact reason hiccups occur after hair transplantation is not established. The authors of the 2,896-patient paper discussed irritation within the cervical/phrenic hiccup reflex pathway as a possible explanation, but the study did not test the mechanism. The cause therefore remains uncertain, and nerve irritation is only one proposed explanation.
Short-lived hiccups are usually more of a nuisance than a serious complication. If they persist, repeatedly return, interfere with eating, drinking or sleep, or occur alongside breathing difficulty, chest pain or other concerning symptoms, the transplant team or another clinician should assess them before prescription treatment is used.
Allergic reaction
True allergic reactions during hair transplantation appear very rare. In a 10-year primary series of 2,896 hair-transplant patients, the authors recorded no major or life-threatening complications, including no reported anaphylaxis. Because allergy was not the study’s primary endpoint, the finding does not provide a precise incidence estimate.
An allergic reaction is different from expected postoperative swelling or a vasovagal episode. The same transplant series describes early facial swelling with hives, breathing difficulty or hypotension as concerning for allergy. That distinction matters because ordinary forehead and eyelid edema can occur after transplantation without representing an allergic response.
Suspected reactions to local anesthetics also need careful interpretation. In a 10-year anesthesia-allergy clinic study, only 6 of 68 patients referred after suspected hypersensitivity reactions to local anesthetics had positive allergy testing. That study was not conducted in hair-transplant patients, but it shows why fainting, palpitations or other peri-procedural symptoms should not automatically be labeled an allergy.
Patients should tell the surgical team about previous reactions to anesthetics, antibiotics, pain medicines, antiseptics or other products used around procedures. New hives, rapidly developing facial or throat swelling, wheezing, breathing difficulty or collapse during or soon after surgery requires immediate medical assessment. The next sections separate allergic reactions from non-allergic drug effects and anesthetic toxicity.
Drug reaction
Drug reactions after hair transplantation are uncommon in published series, but they can be serious. In a 73-patient retrospective hair-restoration study, one patient developed a severe reaction to postoperative cefotaxime that caused left-temporal skin necrosis and permanent scarring; only seven patients in that cohort underwent FUE.
That report is useful because it documents that a medication given around hair-restoration surgery can itself cause a significant complication. However, the study included predominantly FUT procedures and had follow-up data for only 73 of 197 patients treated, so it does not provide a dependable incidence rate for modern FUE.
Drug interactions matter as well. In a separate 2,896-patient hair-transplant series, one patient taking propranolol developed a hypertensive crisis after receiving local anesthetic containing adrenaline; the authors attributed the event to that combination. This was one observed case, not evidence that every patient taking a beta blocker will have the same reaction.
A drug reaction is also not automatically an allergy. Adverse effects can include medication intolerance, dose-related effects or interactions with other drugs. Patients should therefore give the transplant team a complete list of prescription medicines, over-the-counter products and supplements before surgery, and should not stop or change prescribed medication without appropriate medical advice.
Anaesthetic reaction
Serious anaesthetic reactions during hair transplantation are rare but can be life-threatening. A 2021 case report described a 31-year-old man who developed a generalized tonic-clonic seizure about 10 minutes after bupivacaine was injected during transplantation; he required intubation and intravenous lipid treatment but was discharged neurologically intact 48 hours later.
The authors diagnosed local anaesthetic systemic toxicity (LAST), not an allergic reaction. The amount of bupivacaine used was unknown, so the case cannot establish a toxic dose threshold or an incidence rate. The patient developed continuing seizures, severe acidosis and tachycardia before receiving lipid-emulsion treatment; he became hemodynamically stable within about one hour.
Larger clinical series provide useful context. A 2,896-patient hair-transplant series reported no major or life-threatening intraoperative complications. Together, the evidence shows that serious local-anaesthetic toxicity can occur, but it does not provide a dependable modern FUE incidence rate for LAST. Accurate dosing, monitoring and the ability to recognize and respond to toxicity are therefore important parts of procedural safety.
Vision changes
Vision-threatening complications after hair transplantation appear exceptionally rare, but published cases show they can occur. In a 2024 case report, a 53-year-old man developed blurry vision one week after transplantation during MRSA sepsis; visual acuity fell to hand-motion level in one eye before treatment restored vision to baseline.
In that case, blood cultures grew methicillin-resistant Staphylococcus aureus and examination showed significant inflammation inside both eyes. Treatment included intravenous antibiotics and injections into the eyes, while a purulent staple was removed from the recent transplant site. The infection later recurred, but vision ultimately returned to baseline, with mild residual optic-nerve pallor and retinal changes in the left eye. This establishes that serious ocular complications can occur in the setting of severe post-transplant infection, but a single case cannot provide an incidence rate.
Double vision has also been reported. A 2025 case report described a healthy 47-year-old man who developed vertical diplopia five days after hair-replacement surgery and was diagnosed with a right fourth-nerve palsy. His visual acuity remained 20/20 in both eyes, and the diplopia resolved without treatment by seven months. The authors hypothesized that prolonged upright posture after surgery, together with a pre-existing anatomical variant called a mega cisterna magna, may have contributed; they did not establish that the transplant itself caused the nerve palsy.
These reports are too sparse to calculate a dependable risk of vision changes after modern FUE. However, new blurred or double vision, a substantial reduction in vision, or visual symptoms occurring alongside fever or other systemic illness should not simply be assumed to be normal postoperative swelling and warrants prompt medical assessment.
Vascular compromise
Vascular injury after hair transplantation is exceptionally rare, but abnormal artery-to-vein connections have been documented. A 2023 case report described a 50-year-old man who developed a painful, disabling scalp swelling two years after transplantation; CT angiography confirmed an arteriovenous fistula involving superficial temporal and occipital artery branches.
An arteriovenous fistula (AVF) is an abnormal direct connection between an artery and a vein. In the 2023 case, the fistula was successfully closed using endovascular and percutaneous embolization, and the patient remained well at one-month follow-up. This is a single case, however, and does not provide an incidence rate for contemporary FUE.
Hair-transplant-associated vascular injuries have also been documented in older techniques. A donor-site fistula case report described a large AVF after punch-graft transplantation that was demonstrated on arteriography and localized with Doppler ultrasound before operative correction. Separately, serial angiography of pulsating nodules after punch hair grafting identified them as pseudoaneurysms. These older reports confirm that vascular injury can occur, but they do not tell us how often it happens with modern FUE.
A new pulsating or progressively enlarging scalp swelling, visibly enlarged vessels, a palpable vibration, an audible whooshing sound, or persistent focal pain after transplantation should be assessed rather than assumed to be routine healing. Depending on the suspected problem, Doppler ultrasound, CT angiography or other vascular imaging may be needed, and documented cases have been treated with either surgery or endovascular embolization.
Thrombosis
Thrombosis appears to be an exceptionally uncommon reported complication of hair restoration surgery, but it has occurred. A 2008 case report documented deep-vein thrombosis with pulmonary embolism after a hair-restoration procedure. Published hair-transplant literature does not provide a reliable modern FUE incidence rate for this event.
A deep-vein thrombosis (DVT) is a clot forming in a deep vein, usually in a leg; a pulmonary embolism (PE) occurs if part of a clot travels to the lungs. The published hair-restoration case confirms that this complication is possible after surgery, but a single report cannot show how often it occurs or prove which perioperative factor caused it.
Medication management matters because some patients arrive for transplantation already taking anticoagulant or antiplatelet therapy for significant cardiovascular or clotting risk. In a 2012 primary series, 25 men with cardiovascular disease underwent 46 hair-transplant operations; antithrombotic drugs were managed according to individualized protocols, and all procedures were completed without cardiovascular events. One operation involved a patient with a history of pulmonary embolism.
That does not mean patients should continue, reduce or stop blood-thinning medication on their own. The relevant lesson is that the bleeding risk from hair transplantation has to be weighed against the clotting risk of interrupting treatment, with the prescribing clinician involved in that decision. Unilateral leg swelling or pain, sudden shortness of breath, chest pain, coughing blood or unexplained collapse after surgery requires urgent medical assessment.
Sepsis
Sepsis after hair transplantation is rare enough that dependable incidence data are unavailable, but it has been documented. In a 2024 case report, a 53-year-old man developed fever and blurred vision one week after transplantation; blood cultures grew MRSA, and intravenous antibiotics were required for systemic infection.
The same patient developed bilateral endogenous endophthalmitis, meaning the bloodstream infection had seeded the eyes. Treatment included systemic antibiotics, intraocular vancomycin and removal of a purulent staple from the recently transplanted area. His systemic and ocular symptoms improved, although bacteremia recurred about three months later and required repeat systemic and intraocular antibiotic treatment. His vision ultimately returned to baseline.
This is not the only firsthand report. An earlier primary case report of Staphylococcus aureus sepsis complicating a hair transplant was published in 2001. Two individual reports separated by more than two decades establish that systemic infection can occur, but they do not provide a denominator from which a modern FUE sepsis rate can be calculated.
Large transplant series help put that rarity into perspective. In the 10-year series of 2,896 patients, two postoperative infections were recorded and the authors reported no major or life-threatening complications. That does not prove the risk of sepsis is zero. Fever accompanied by rapidly worsening systemic illness after transplantation warrants urgent medical assessment rather than being treated as an expected part of recovery.
Cardiac arrest
Cardiac arrest has been documented during and shortly after hair transplantation, but no reliable modern FUE incidence rate exists. A 2025 peer-reviewed forensic case series described three men aged 28, 34 and 43 who developed fatal anaesthesia-related complications around hair-transplant procedures; cardiac arrest occurred in all three cases.
The three cases were selected from forensic files of patients referred after complications, so the study cannot tell us how often cardiac arrest occurs among all hair-transplant patients. All three procedures were performed outside operating rooms and without an anaesthesiologist. The timing also differed: one arrest occurred during the procedure, another followed chest pain and ventricular fibrillation, and the third occurred around two hours after the patient left the clinic.
Broader clinical evidence is more reassuring. A 10-year series of 2,896 hair-transplant patients reported no significant life-threatening or major complications. The evidence therefore confirms that cardiac arrest can occur around hair transplantation, but it does not provide a dependable percentage for modern FUE or show that every reported arrest has the same cause.
Hair transplant death rate & mortality risk
Can you die from a hair transplant? Yes, but published fatalities are exceptionally sparse and no reliable hair transplant death rate exists. A 2025 peer-reviewed forensic case series described three men, aged 28, 34 and 43, who died after anaesthesia-related complications associated with hair-transplant procedures performed outside operating rooms.
The study reviewed forensic files referred after hair-transplant complications rather than following a general population of transplant patients, so three deaths in three selected cases cannot be turned into a mortality percentage. All three procedures were performed without an anaesthesiologist. One patient developed cyanosis and cardiac arrest during the procedure and died three days later; another developed chest pain followed by ventricular fibrillation and cardiac arrest; the third suffered cardiac arrest around two hours after leaving the clinic. The case files differed clinically, so they do not establish one single mechanism of death.
Larger clinical series provide reassuring context without defining the true mortality risk. In a 10-year series of 2,896 hair-transplant patients, the authors reported no significant life-threatening or major complications. That finding cannot support a universal 0% mortality rate because an event this rare may not appear even in a series of several thousand patients.
So, what is the hair transplant death rate? Current primary evidence does not provide a dependable population-level percentage for modern FUE. Published fatal cases establish that death is possible, while larger clinical series show that catastrophic events may be absent across thousands of procedures. The evidence therefore supports describing mortality as documented but not reliably quantifiable.
Hair transplant side effects long term
When people ask about long term side effects of hair transplant surgery, the main concerns are changes that can remain after routine healing has finished. Potential lasting problems include donor depletion, visible scarring or texture change, pigment alteration, poor graft growth, unnatural density or hair direction, and persistent numbness, neuropathic pain or, very rarely, neuroma.
These are different from acute complications such as infection, thrombosis, sepsis, anaesthetic toxicity or cardiac arrest, which occur around the procedure rather than slowly developing years later. Some long-term cosmetic problems can be revised, but donor follicles are finite and scarring, graft failure or permanent nerve symptoms may not be completely reversible.
Ongoing native hair loss also matters. A transplant redistributes existing follicles; it does not stop androgenetic hair loss elsewhere on the scalp. Future thinning can therefore change the balance of density around a transplanted area and may affect whether medication, additional surgery or no further treatment is the best next step.
Key takeaways on hair transplantation side effects
Most hair transplant side effects are temporary healing effects rather than lasting complications. Redness, swelling, scabbing, tenderness, itching, temporary numbness and shedding can all occur during recovery. The important distinction is between symptoms that are expected to improve and changes that persist, worsen or fall outside the normal healing pattern.
The evidence also shows why simple complication percentages can be misleading. Some problems, such as folliculitis, have been measured in larger patient series, while others—including neuroma, vascular injury, thrombosis, sepsis, cardiac arrest and death—are documented mainly through isolated cases or small series. For many rare events, there is not enough modern FUE evidence to give a dependable incidence rate.
The complications most likely to create a lasting cosmetic or functional problem include poor graft growth, unnatural placement or density, donor overharvesting, visible scarring or pigment change, and persistent nerve symptoms. Serious systemic complications are a different category: they are medical emergencies around the time of surgery rather than long-term cosmetic side effects, and published evidence suggests they are exceptionally uncommon rather than impossible.
If you are deciding whether surgery is right for you, it is worth weighing the pros and cons of hair transplant surgery alongside these risks, including the recovery period, finite donor supply, progression of existing hair loss, permanence of transplanted follicles and the possibility of needing further treatment. Careful candidate selection, realistic planning, full disclosure of medications and medical history, and prompt review of anything that is not healing as expected all matter.
FAQs
Are hair transplants dangerous?
Hair transplants are generally low-risk for medically suitable patients, but they are still surgical procedures and can cause complications. Most reported problems are temporary or local, while serious events such as severe infection, anaesthetic toxicity, thrombosis, cardiac arrest and death are documented far more rarely in the published evidence.
In the 10-year series of 2,896 hair-transplant patients used throughout this article, no major or life-threatening complications were reported. That is reassuring, but it does not make the risk zero. Individual suitability, medication use, cardiovascular history, infection risk and the way anaesthesia is administered all matter.
Can hair transplant cause cancer?
Standard autologous hair transplantation is not established as a cause of cancer. A 1979 case report described basal cell carcinoma developing at a recipient plug five years after transplantation, but the author considered the relationship probably coincidental. No dependable evidence shows modern FUE increases cancer risk.
This should be distinguished from synthetic hair implantation, which places artificial fibers rather than a patient’s own follicles. A peer-reviewed report of two additional squamous cell carcinomas after synthetic hair implantation noted that several earlier cases had also been published, while explicitly stating that the available data are insufficient to establish causation. Synthetic hair implantation is a different procedure and does not establish a cancer risk from autologous FUE.
Can you die from a hair transplant?
Yes, death after hair transplantation has been documented, but it appears exceptionally rare and there is no reliable hair transplant death rate for modern FUE. Large clinical series report no life-threatening events, while isolated fatal cases show the risk is not zero and can involve serious peri-procedural complications.
This is why thorough medical screening, full disclosure of medications and health history, and treatment in an appropriately supervised medical setting matter. The available evidence does not show a precise mortality rate, but large clinical series suggest life-threatening events are exceptionally uncommon rather than impossible.